• Synthelis

  Participated · Equity · Jan 2014

  Synthelis Biotech is an Isère-based startup focused on acellular (cell-free) manufacturing of complex proteins intended for therapeutic drugs and vaccines. Its proprietary technology aims to streamline and scale the production of proteins that are typically difficult to express with traditional cell-based systems. By eliminating living cells from the process, the company targets faster development cycles and greater control over product quality. The firm plans to move from laboratory-scale proof-of-concept to industrial-scale manufacturing. Recent state backing is intended to accelerate this industrialization phase. Although specific revenue, customer, or production metrics were not disclosed, the new support underlines the company’s transition from R&D to commercialization. Future efforts will likely focus on building production capacity and forging partnerships with biotech and pharmaceutical clients.

No current team members are available.